Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.06

€3.06

0.660%
0.02
0.660%
-
 
11:15 / Tradegate WKN: A11QVV / Name: Heidelberg Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Heidelberg Pharma AG Stock

Heidelberg Pharma AG gained 0.660% compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Heidelberg Pharma AG stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Heidelberg Pharma AG in the next few years

Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Heidelberg Pharma AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Heidelberg Pharma AG 0.660% -1.299% -0.977% -27.791% -17.391% -61.076% -5.000%
CytoTools AG -11.930% 65.644% 45.161% -76.724% -29.870% -96.707% -94.328%
Nanorepro AG -1.400% 3.170% -4.021% -15.962% -13.107% -84.958% 54.310%
Vivoryon Therapeutics N.V. -1.930% -4.475% -9.074% -96.508% -93.893% -96.483% -97.711%

Comments

Buy Heidelberg Pharma AG
Show more

systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more

Buy Heidelberg Pharma AG
Show more

News

EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023